Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic sclerosis
•
Scleroderma
If a patient has progression of scleroderma-ILD on MMF alone, and you are planning to start tocilizumab, would you continue MMF at a lower dose to maintain skin softening?
Related Questions
What considerations do you take when using prednisone in patients with systemic sclerosis?
How do you approach symptom control in a patient with diffuse cutaneous systemic sclerosis (dcSSc) and rapidly progressive skin disease?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency would you recommend treatment with endovenous laser/ablation?
How would you approach management of a patient with rapidly progressive systemic sclerosis with worsening skin disease, myositis, arthritis, dysphagia and failure to thrive developing within 6 months?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
What would be your approach to a patient with Scleroderma/Myositis overlap syndrome (+anti-Ku) and active inflammatory eye disease despite high dose mycophenolate?
What is the approach to use of ACE inhibitors for suspected scleroderma renal crisis in patients with only mildly elevated BP and renal artery stenosis?
How would you manage a patient with diffuse Systemic Sclerosis who develops severe rapidly progressive calcinosis?
When do you consider Mesna for patients taking oral cyclophosphamide?
How do you manage trigeminal sensory neuropathy in a patient with systemic sclerosis?
